Website being updated with information on Gibson Oncology’s important new developments in Brain Cancer
- Orphan Drug Designation (ODD) from the FDA for both Glioblastoma and multiple types of Gliomas.
- Finalizing discussions with the NIH on conducting Phase II Clinical Trials in GBM.
- Clinical trial based on basic research performed by the NIH, by Purdue University, by the Robert Preston Tisch Brain Tumor Center at Duke University, and by Gibson Oncology.
- Multiple Phase I FDA clinical trials completed by the National Cancer Institute.
Gibson Oncology will release more specific information when granted permission from our partners.
Mark C. Rogers, M.D., M.B.A.
Randall Riggs
Theodore C. Solomon
Chief Financial Officer
Elizabeth London Rogers, M.D.
Clifford T. Solomon M.D.
Chief Medical Officer
Mark S. Cushman, Pharm.D., Ph.D
Chief Scientific Officer
Scientific Advisory Committee
Mark S. Cushman, PhD., PharmD
Distinguished Professor of Medicinal Chemistry at Purdue University Chief Scientific Officer Board Member
Manmeet Ahluwalia, MD, MBA
Chief of Solid Tumor Medical Oncology, Chief Scientific Officer & Deputy Director Miami Cancer Institute
Desmond A. Brown, MD., PhD
Assistant Clinical Investigator & Head of Neurosurgical Oncology at National Institute of Neurological Disorders and Stroke (NINDS)
Pooran Chand, PhD
CEO and Co-Founder of Therachem Research Medialab
Yves Pommier, MD., PhD.
Senior Investigator Development Therapeutics Branch NCI/CCR
Matthew Waitkus, PhD
Assistant Professor in Neurosurgery Assistant Professor of Pathology Member of the Duke Cancer Institute
Graeme F. Woodworth, M.D., FAANS, FACS
Professor and Chair, Department of Neurosurgery Director, Brain Tumor Treatment and Research Center University of Maryland School of Medicine
Jing Wu, M.D., Ph.D.
Center for Cancer Research-NIH Lasker Clinical Research Scholar Neuro-Oncology Branch
Danzhou Yang, PhD
Distinguished Professor |Medicinal Chemistry and Molecular Pharmacology, Analytical Chemistry, Biochemistry at Purdue University
Michael Zinner, MD
Chief Executive Officer & Medical Director, Miami Cancer Institute Former Professor & Chair of the Dept of Surgery, Harvard Medical School